Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...
New signing Omar Marmoush scored a scintillating first-half hat-trick as Manchester City rediscovered their spark in an emphatic 4-0 win over Newcastle. The £59million January signing from ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...
SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...
EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron’s share of the degenerative eye disease market, said six-month results show its ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call.
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target of $950.00. The company’s shares closed ...
Jaden Smith's infamous house hat is opening doors. In fact, his mom Jada Pinkett Smith was head over heels about the unique headpiece, which the 26-year-old recently wore alongside a black Louis ...
Today, a brief rundown of news involving Amgen and Regeneron, as well as updates from Valneva, Turnstone Biologics and AdvanCell that you might have missed. Pioneers like Alnylam Pharmaceuticals have ...
It notched a convincing beat on net income. The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback